Article Details

ASCO: Merck's Keytruda targets Pfizer's shaky Sutent post-surgery use in kidney cancer

Retrieved on: 2021-06-03 21:11:15

Tags for this article:

Click the tags to see associated articles and topics

ASCO: Merck's Keytruda targets Pfizer's shaky Sutent post-surgery use in kidney cancer. View article details on hiswai:

Excerpt

Since 2017, Pfizer's kinase inhibitor Sutent has been approved to help prevent tumors from returning in high-risk kidney cancer patients after surgery.

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up